Madrigal Appoints Johnson & Johnson R&D Chief John Reed to Board

GlobeNewswire··US·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Madrigal Pharmaceuticals has appointed John C. Reed, M.D., Ph.D., to its board of directors. Dr. Reed is Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson and a member of its Executive Committee. Madrigal’s Chairman Julian Baker and CEO Bill Sibold highlighted his track record in advancing innovative medicines and his strategic leadership, which they expect will support the company’s growth and its MASH pipeline, including the launched therapy Rezdiffra.

Impact on assets 2

Biotech & Genomic Medicine▲ · 2 stocks
© 2026 MarketIVNews